当前位置: 首页 > 期刊 > 《中华现代内科学杂志》 > 2006年第3期
编号:10959344
布地奈德混悬液吸入治疗慢性阻塞性肺疾病急性加重期的临床观察
http://www.100md.com 《中华现代内科学杂志》 2006年第3期
布地奈德,,慢性阻塞性肺疾病;急性加重期;布地奈德,1资料与方法,2结果,3讨论,【参考文献】
     【摘要】 目的 探讨雾化吸入布地奈德混悬液治疗慢性阻塞性肺疾病(COPD)急性加重期患者的疗效。方法 40例COPD急性加重期患者随机分成治疗组和对照组各20例,分别给予布地奈德混悬液及全身性应用糖皮质激素。观察2组治疗前后呼吸困难、肺功能、动脉血气变化及副作用的情况。结果 治疗组和对照组治疗前后的呼吸困难、肺功能、动脉血气变化均差异无显著性,雾化吸入布地奈德混悬液治疗组的副作用明显少于全身应用糖皮质激素的对照组。结论 雾化吸入布地奈德混悬液是治疗COPD急性加重期患者安全有效的方法,值得推广。

    【关键词】 慢性阻塞性肺疾病;急性加重期;布地奈德

    Clinlcal observation of nebulized budesonide suspension in treating acute exacerbations of chronic obstructive pulmonary disease

    HU Guo-ping.

    Department of Respiratory,Changzheng Hospital Zhabei Branch,Shanghai 200070,China

    【Abstract】 Objective To Compare the effects of nebulized budesonide suspension and systemic glucocorticoids on acute exacerbation of chronic obstructive pulmonary disease.Methods Forty cases with acute exacerbation of COPD were randomly divided into two groups,treated with nebulized budesonide suspension or systemic glucocorticoids.To observe the changes and side-effects of decompensation,pulmonary function,blood gas before and after the treatment.Results The two groups had no significant differences on decompensation,pulmonary function and blood gas in the course.The treatment group with nebulized budesonide has fewer side-effects than that in the control group with systemic glucocorticoids.Conclusion Nebulized budesonide is worth spreading in treating acute exacerbation of chronic obstructive pulmonary disease as a safe and efficiency method. ......

您现在查看是摘要页,全文长 5889 字符